Carter Caldwell
Program Director @ Penn Medicine Co-Investment Fund
Philadelphia, United States
Carter Caldwell is a seed investor at Penn Medicine Co-Investment Fund in Philadelphia focused on Health Care and Biotechnology. As the Penn Medicine Co-Investment Program’s inaugural Director, Carter drives Penn Medicine's investments in the cell therapy, gene therapy, mRNA, lipid nanoparticle, and connected health spinouts. Utilizing multiple decades of experience as both an entrepreneur and an investor, he sources investment opportunities, helps spinouts raisecapital, manages relationships with co-investors, completes due diligence, and supports the governance of the funded companies.Carter has spent much of his career in venture capital and focused on new investments in the Healthcare IT, SaaS and Enterprise Software, AI, and Fintech industries, among others. He was previously a Managing Director with Cross Atlantic Capital Partners, a venture capital firm with 4 funds and over $500 million under management.He has a strong technology background, having founded and managed two software companies. Carter founded and served as COO of Quazant Technology, the developer of the Transaction Accelerator®, a high-speed transaction-processing database used in the Financial Services, Telecommunications and Enterprise Resource Planning industries. Prior to Quazant, Carter served as Director of Corporate Development and Product Manager at Acorn Systems, an activity-based cost analysis software and services company which was acquired by Ignite Technologies in July 2014.Carter holds an MBA from Columbia University and a BA in Philosophy, Politics and Economics from the University of Pennsylvania.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Carter Caldwell invests in
Stages Carter Caldwell invests in
Countries Carter Caldwell invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 6 (46%)
- Biotechnology 6 (46%)
- Therapeutics 4 (31%)
- Medical 3 (23%)
- Software 2 (15%)
Stage
- Seed 4 (31%)
- Series A 3 (23%)
- Series B 3 (23%)
- Series C 1 (8%)
- Funding Round 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $21.5M / Jan 01, 2025 | ||
| BlueWhale Bio is spinout from the University of Pennsylvania to accelerate the use of cell-based therapies by manufacturing innovation. | $18M / Seed / Sep 07, 2023 | ||
| Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $30M / Series C / Sep 21, 2022 | ||
| Innervace is a developer of a regenerative therapy company designed to develop implantable tissue-engineered brain pathways for neurodegenerative disorders.The company is focused on the development and commercialization of anatomically inspired living scaffolds for brain pathway reconstruction, and its lead clinical product is a tissue-engineerednigrostriatal pathway that mimics the lost nigrostriatal pathway in patients with Parkinson's disease. This gives patients access to technology that specifically reconstructs brain pathways rather than just masking symptoms temporarily.Innervace was established in 2018 by in Philadelphia, Pennsylvania | $40M / Series A / Sep 08, 2022 | ||
| Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings. | $10M / Seed / Jun 07, 2022 | ||
| CareAlign provides clinicians with an intuitive, patient-centric task management tool to track, manage and coordinate clinical care. Easily assign, date and time tasks, categorize them for when they are due, view cleared tasks and more. | $2.3M / Seed / Nov 30, 2021 | ||
| Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $76M / Series A / May 18, 2021 | ||
| Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $12M / Series B / Mar 01, 2021 | ||
| Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $5.5M / Seed / Mar 13, 2020 | ||
| Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation anddirection in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications. | $75M / Series B / Oct 31, 2019 | ||
| See all 13 investments → | |||
Co-Investors
Agent Capital
7 deals together
Tellus BioVentures
5 deals together
BrightEdge Fund
3 deals together
HealthCap
3 deals together
The Mark Foundation for Cancer Research
3 deals together
4BIO Capital
2 deals together
Penn Medicine Co-Investment Program makes investments in faculty-driven cell therapy, gene therapy, and connected health companies
Penn Medicine Co-Investment Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Carter Caldwell
Program Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Carter Caldwell invest in?
Carter Caldwell invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Carter Caldwell?
Public channels for Carter Caldwell include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Carter Caldwell last invest?
The most recent investment recorded for Carter Caldwell closed in Jan 2025. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
